All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
Rashad, 2021 2.86 [1.36; 6.01]
Rashad, 2021 0.35 [0.17; 0.74]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Tang X, 2020 0.98 [0.93; 1.02]
0.97 [0.74 ; 1.27 ] GLUCOCOVID, 2020, Jamaati, 2021, Metcovid, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 8 58% 1,367 moderate not evaluable death or transfer to ICUdetailed results GLUCOCOVID, 2020 0.68 [0.37; 1.25]
0.68 [0.37 ; 1.25 ] GLUCOCOVID, 2020 1 0% 63 NA not evaluable deathsdetailed results CAPE-COVID, 2020 0.45 [0.20; 1.02]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
Ranjbar, 2021 0.40 [0.15; 1.08]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tang X, 2020 0.98 [0.93; 1.02]
0.85 [0.73 ; 0.99 ] CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Edalatifard, 2020, GLUCOCOVID, 2020, Jamaati, 2021, Metcovid, 2020, Ranjbar, 2021, Rashad, 2021, Rashad, 2021, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Steroids-SARI, 2020, Tang X, 2020 15 64% 8,475 moderate low deaths (time to event analysis only)detailed results Edalatifard, 2020 0.29 [0.15; 0.56]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
0.78 [0.43 ; 1.40 ] Edalatifard, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 5 83% 858 serious not evaluable clinical deteriorationdetailed results CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
Tang X, 2020 1.00 [0.13; 7.45]
0.67 [0.44 ; 1.03 ] CODEX (Tomazini), 2020, Tang X, 2020 2 0% 385 moderate not evaluable clinical improvementdetailed results Edalatifard, 2020 12.00 [2.39; 60.20]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
Tang X, 2020 1.04 [0.67; 1.62]
1.44 [0.89 ; 2.33 ] Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 4 65% 686 serious not evaluable clinical improvement (14-day)detailed results REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Tang X, 2020 1.33 [0.57; 3.11]
1.18 [0.87 ; 1.59 ] REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 3 0% 584 serious not evaluable clinical improvement (time to event analysis only)detailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
1.09 [0.71 ; 1.68 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 4 59% 5,783 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
1.19 [0.86 ; 1.64 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020 2 37% 6,574 moderate not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
Jamaati, 2021 1.38 [0.45; 4.20]
Metcovid, 2020 1.19 [0.56; 2.49]
Ranjbar, 2021 0.36 [0.13; 0.97]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
0.82 [0.61 ; 1.08 ] CAPE-COVID, 2020, Jamaati, 2021, Metcovid, 2020, Ranjbar, 2021, RECOVERY dexamethasone, 2020 5 17% 5,891 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
4.89 [1.15 ; 20.79 ] Jamaati, 2021 1 0% 50 NA not evaluable viral clearance detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable viral clearance (time to event analysis only)detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable ICU admissiondetailed results GLUCOCOVID, 2020 0.85 [0.27; 2.67]
Tang X, 2020 1.00 [0.13; 7.45]
0.88 [0.33 ; 2.39 ] GLUCOCOVID, 2020, Tang X, 2020 2 0% 150 serious not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
Edalatifard, 2020 0.81 [0.11; 6.17]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
1.06 [0.41 ; 2.77 ] CODEX (Tomazini), 2020, Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 4 17% 841 serious not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
0.91 [0.66 ; 1.25 ] CAPE-COVID, 2020, Metcovid, 2020 2 0% 542 moderate not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-21 00:28 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290